Procaps Group Receives Delisting Notice From Nasdaq

Core Viewpoint - Procaps Group, S.A. has received a notice from Nasdaq regarding the delisting of its ordinary shares due to non-compliance with financial reporting requirements, leading to a transition to the OTC Expert Market starting February 4, 2025 [1][2]. Company Overview - Procaps is a leading integrated healthcare and pharmaceutical services company in Latin America, operating in over 50 countries and employing nearly 5,000 people [3]. - The company develops, manufactures, and markets a range of products including over-the-counter pharmaceuticals, prescription drugs, nutritional supplements, and clinical solutions [3].